The severely affected "rescuable" SMA model mice, SMN2;Δ7;Cre-ER;SmnRes/Res, allow tamoxifen-inducible rescue of Type II (moderate) proximal spinal muscular atrophy.
IMR Colony, The Jackson Laboratory
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Recombinase-expressing, Inducible) |
Allele Type |
---|
Transgenic (Hypomorph, Inserted expressed sequence, Humanized sequence) |
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Conditional ready (e.g. floxed), Humanized sequence, No functional change) | Smn1 | survival motor neuron 1 |
These SMN2;Δ7;Cre-ER;SmnRes mice harbor multiple mutations/transgenes.
The Smn rescue allele (SmnRes; also called Smn1 conditional inversion or Smn1 COIN) is a functional null in the non-recombined state. Prior to Cre recombination, no full-length SMN transcript is detected in somatic tissue by RT-PCR. No spontaneous inversion of the allele is reported in the absence of Cre recombinase. The SmnRes allele is designed to revert to a fully functional SMN upon exposure to Cre recombinase.
Mice homozygous for the Tg(SMN2)89 transgene (SMN2+/+), homozygous for the Tg(SMNΔ7)4299 transgene (SMNΔ7+/+), and homozygous for the Smn1tm3(SMN2/Smn1)Mrph mutation (SmnRes/Res) are a moderate Type II SMA mouse model with similar phenotype as Stock No. 005025. Those SMN2+/+;SMNΔ7+/+;SmnRes/Res mice exhibit greatly reduced SMN protein in P4 spinal cord tissue, are born small with neuromuscular defects by 4-5 days old that progress to abnormal gait, hind limb weakness/immobility, and eventually death at approximately 13-17 days of age.
When also harboring a tamoxifen-inducible Cre recombinase (Cre-ER) under control of a ubiquitous promoter [Tg(CAG-CreER)5], mice with SMN2+/+;SMNΔ7+/+; Cre-ER+/-;SmnRes/Res genotype are the severely affected "rescuable" SMA model (SMN2;Δ7;Cre-ER;SmnRes/Res), and exhibit the same moderate Type II SMA phenotype in the absence of tamoxifen. Addition of tamoxifen results in widespread Cre recombinase expression and inversion of the SmnRes allele to the "rescue" conformation. Specifically, Cre recombinase irreversibly inverts the fragment bordered by the lox71 and lox66 sites, and the resulting allele is "rescued" into a format that contains mouse Smn1 exons 1-7 and human SMN2 exon 8. Because the mouse Smn1 exon 7 is efficiently spliced, the majority of the mRNA from the Cre recombinase-induced rescue allele contains mouse Smn1 exon 7. When 4 day old SMN2+/+;SMNΔ7+/+;Cre-ER+/-;SmnRes/Res mice are administered a single tamoxifen dose (75 mg/kg), they gradually gain strength, perform better in a righting reflex assay, and become significantly larger by 17 days old, and have significantly improved lifespan. Such improvements are progressively diminished when administering tamoxifen at later timepoints.
Mice heterozygous for the Smn1tm3(SMN2/Smn1)Mrph mutation (SmnRes/+) and homozygous for the other mutations/transgenes are viable and fertile with no reported abnormalities or symptoms of neuropathology. As such, The Jackson Laboratory Repository Stock No. 008783 is maintained as SMN2+/+;SMNΔ7+/+;Cre-ER+/-;SmnRes/+. A researcher must breed SMN2+/+;SMNΔ7+/+;Cre-ER+/-;SmnRes/+ mice together to generate the severely affected "rescuable" SMA model (SMN2;Δ7;Cre-ER;SmnRes/Res).
The SMN2;Δ7;Cre-ER;SmnRes mice harbor several mutations/transgenes, as described below.
The creation of the Smn rescue allele (SmnRes; also called Smn1 conditional inversion or Smn1 COIN) is described as Stock No. 007249. These mice were maintained upon mixed B6J;129 genetic background prior to being used for breeding as below.
The creation of the Tg(SMN2)89 transgene (SMN2) and Tg(SMNΔ7)4299 transgene (Δ7) are described for the moderate type II SMA mouse model; Stock No. 005025. Note the Tg(SMN2)89 transgene insertion site in on chromosome 6. These mice were bred to and maintained upon an FVB/N-congenic background prior to being used for breeding as below.
The creation of the tamoxifen-inducible ubiquitously expressed Cre transgene (Tg(CAG-CreER)5) is described as Stock No. 004682. These mice were bred to and maintained upon a C57BL/6J-congenic background prior to being used for breeding as below.
To generate the SMN2;Δ7;Cre-ER;SmnRes animals, SmnRes mice were bred to moderate type II SMA mice (Tg(SMN2)89;Smn1+/-;Tg(SMNΔ7)4299). The SMN2;Δ7;SmnRes/+ progeny (not retaining the Smn1- knockout mutation) were identified, and then bred to Tg(CAG-CreER)5 mice. The resulting SMN2;Δ7;Cre-ER;SmnRes/+ offspring (on a mixed C57BL/6;FVB/N;129 genetic background) were then bred together at The Jackson Laboratory Repository as Stock No. 008783.
The Jackson Laboratory Repository Stock No. 008783 colony is maintained as heterozygous for the Smn1tm3(SMN2/Smn1)Mrph mutation (SmnRes/+), homozygous for the Tg(SMNΔ7)4299 transgene (SMNΔ7+/+), homozygous for the Tg(SMN2)89 transgene (SMN2+/+), and hemizygous for the Tg(CAG-CreER)5 transgene (Cre-ER). That is, SmnRes/+;SMNΔ7+/+;SMN2+/+;Cre-ER+/-. A researcher must breed SmnRes/+;SMNΔ7+/+;SMN2+/+;Cre-ER+/- mice together to generate the severely affected "rescuable" SMA model (SMN2;Δ7;Cre-ER;SmnRes/Res).
Expressed Gene | cre/Esr1, Cre recombinase and estrogen receptor 1 fusion gene, |
---|---|
Site of Expression | tamoxifen-inducible cre; widespread pattern of expression; tamoxifen administration will also induce Cre recombination in developing embryos of treated mothers and in cultured cells derived from transgenic mice |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Site of Expression | Grm7Tg(SMN2)89Ahmb |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Site of Expression | Tg(SMN2*delta7)4299Ahmb |
Site of Expression | Following Cre-mediated irreversible inversion of the fragment bordered by the lox71 and lox66 sites, the allele is "rescued" into a format that contains mouse Smn1 exons 1 through 7 and human SMN2 exon 8 and the resulting SMN protein is produced in motor neurons. |
Allele Name | transgene insertion 5, Andrew P McMahon |
---|---|
Allele Type | Transgenic (Recombinase-expressing, Inducible) |
Allele Synonym(s) | CAG-CreEr; CAGG-Cre; CaggCreER; CAGGCre-ER; CAGGCre-ERTM; CAGGCre-ERtm line 5.8; CAGGS-CreER; CAGGS-CreErT; CMV-creERT; Cre-ER; Cre-ERTM; CreESRT; ER-cre; Tg(CAG-cre/Esr1)5Amc; Tg(cre/Esr1)5Amc; Tg:Cag-Cre/Esr1; TgCreER; TgCAGGCreER; uCreERT |
Gene Symbol and Name | Tg(CAG-cre/Esr1*)5Amc, transgene insertion 5, Andrew P McMahon |
Gene Synonym(s) | |
Promoter | ACTB, actin, beta, chicken |
Expressed Gene | cre/Esr1, Cre recombinase and estrogen receptor 1 fusion gene, |
Site of Expression | tamoxifen-inducible cre; widespread pattern of expression; tamoxifen administration will also induce Cre recombination in developing embryos of treated mothers and in cultured cells derived from transgenic mice |
Strain of Origin | (C57BL/6 x CBA)F1 |
Chromosome | UN |
General Note | Homozygous transgenic mice are not viable or fertile. Hemizygous transgenic mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. In transgenic mice the mutant mouse estrogen receptor does not bind natural ligand at physiological concentrations but will bind the synthetic ligand, 4-hydroxytamoxifen. Restricted to the cytoplasm, the Cre/Esr1 fusion protein can only gain access to the nuclear compartment after exposure to tamoxifen. When crossed with a strain containing loxP sites flanking a sequence of interest, tamoxifen induced, Cre-mediated targeted deletions are generated in the offspring. Tamoxifen administration will induce Cre recombination in developing embryos of treated mothers and in cultured cells derived from transgenic mice. Note that this transgene does not contain the cre/ERT2 fusion but was mistakenly referred to by the synonym CAG-CreERT2 in publication. J:136965 Note that this transgene does not contain the cre/ERT2 fusion but was mistakenly referred to by the synonym CAGG-CreERT2 in publication. J:130851 |
Molecular Note | This transgene expresses a fusion protein consisting of Cre recombinase joined to the ligand-binding domain of a mouse estrogen receptor modified to bind to 4-hydroxytamoxifen, but not to endogenous estrogen. The CAG promoter, containing a chicken beta actin promoter/enhancer coupled with the cytomegalovirus immediate-early (CMV-IE) enhancer, drives high levels of expression in most tissues. In the presence of tamoxifen, the fusion protein is transported into the nucleus, where cre can excise loxP-flanked segments from conditionally modified genes. |
Mutations Made By | Shigemi Hayashi, Columbia University |
Allele Name | transgene insertion 89, Arthur H M Burghes |
---|---|
Allele Type | Transgenic (Hypomorph, Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | SMN2 |
Gene Symbol and Name | Grm7, glutamate receptor, metabotropic 7 |
Gene Synonym(s) | |
Promoter | SMN2, survival of motor neuron 2, centromeric, human |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Site of Expression | Grm7Tg(SMN2)89Ahmb |
Strain of Origin | FVB/N |
Chromosome | 6 |
Molecular Note | A 35.5 kb genomic fragment containing the human survival motor neuron 2 (SMN2) gene and promoter was used for the transgene. The transgene is ubiquitously expressed in all tissues examined by Northern blot analysis. Line 89 carries 1 copy of the transgene integrated into intron 4 of the gene. RT-PCR confirmed reduced expression of the gene the transgene is integrated into. |
Mutations Made By | Arthur Burghes, The Ohio State University |
Allele Name | transgene insertion 4299, Arthur H M Burghes |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | SMNdelta7; Tg(SMN1*delta7)4299Ahmb |
Gene Symbol and Name | Tg(SMN2*delta7)4299Ahmb, transgene insertion 4299, Arthur H M Burghes |
Gene Synonym(s) | |
Promoter | SMN2, survival of motor neuron 2, centromeric, human |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Site of Expression | Tg(SMN2*delta7)4299Ahmb |
Strain of Origin | FVB/N |
Chromosome | UN |
Molecular Note | The transgene contains a human SMN2 promoter and a human SMN2 cDNA (SMNdelta7) that lacks exon 7. There are 14 copies of this allele integrated into the genome. |
Mutations Made By | Arthur Burghes, The Ohio State University |
Allele Name | targeted mutation 3, Andrew Murphy |
---|---|
Allele Type | Targeted (Conditional ready (e.g. floxed), Humanized sequence, No functional change) |
Allele Synonym(s) | hybrid rescue allele; SmnINV; SmnRes; Smn1 COIN (conditional inversion) |
Gene Symbol and Name | Smn1, survival motor neuron 1 |
Gene Synonym(s) | |
Site of Expression | Following Cre-mediated irreversible inversion of the fragment bordered by the lox71 and lox66 sites, the allele is "rescued" into a format that contains mouse Smn1 exons 1 through 7 and human SMN2 exon 8 and the resulting SMN protein is produced in motor neurons. |
Strain of Origin | (129S6/SvEvTac x C57BL/6NTac)F1 |
Chromosome | 13 |
Molecular Note | Exons 7 and 8 of the mouse Smn1 (survival motor neuron 1) gene and a several hundred base pairs of flanking sequence were replaced with a fragment containing, in order: 1) an inverted lox71 site; 2) exon 7 from the human SMN2 (survival of motor neuron 2, centromeric) gene flanked by several hundred base pairs of intron sequence; 3) an inverted copy of mouse Smn1 exon 7 flanked by several hundred base pairs of intron sequence; 4) a lox66 site; 5) an FRT site remnant from a deleted selection cassette; and 6) human SMN2 exon 8 including the 3'UTR and polyA signal with several hundred base pairs of flanking sequence. The engineered allele expresses a hybrid Smn1 gene containing mouse Smn1 exons 1 through 6 and human SMN2 exons 7 and 8. The human SMN2 exon 7 is skipped in the majority of mRNA derived from the hybrid gene due to a single base pair difference in human SMN2 exon 7, compared to human SMN1 exon 7. Following Cre-mediated irreversible inversion of the fragment bordered by the lox71 and lox66 sites, the allele is "rescued" into a format that contains mouse Smn1 exons 1 through 7 and human SMN2 exon 8. Because the mouse Smn1 exon 8 is efficiently spliced, the majority of the mRNA from the rescue allele after Cre-mediated inversion contains mouse Smn1 exon 7. |
Mutations Made By | Nicole Graiff, Regeneron |
Mice heterozygous for the Smn1tm3(SMN2/Smn1)Mrph mutation (SmnRes/+) and homozygous for the other mutations/transgenes are viable and fertile with no reported abnormalities or symptoms of neuropathology. As such, The Jackson Laboratory Repository Stock No. 008783 is maintained as heterozygous for the Smn1tm3(SMN2/Smn1)Mrph mutation (SmnRes/+), homozygous for the Tg(SMNΔ7)4299 transgene (SMNΔ7+/+), homozygous for the Tg(SMN2)89 transgene (SMN2+/+), and hemizygous for the Tg(CAG-CreER)5 transgene (Cre-ER). That is, SmnRes/+;SMNΔ7+/+;SMN2+/+;Cre-ER+/-. A researcher must breed SmnRes/+;SMNΔ7+/+;SMN2+/+;Cre-ER+/- mice together to generate the severely affected "rescuable" SMA model (SMN2;Δ7;Cre-ER;SmnRes/Res).
When using the SMN2;Δ7;Cre-ER;SmnRes , SMN2;Δ7;Cre-ER;SmnCOIN , Delta 7 mouse with hybrid rescue allele and tamoxifen inducible Cre mouse strain in a publication, please cite the originating article(s) and include JAX stock #008783 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(CAG-cre/Esr1*)5Amc, Heterozygous or wildtype for Smn1<tm3(SMN2/Smn1)Mrph> Hemizygous for Tg(SMN2*delta7)4299Ahmb Homozygous for Tg(SMN2)89Ahmb |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.